	US 12,220,398 B2
	Tumor therapeutic agent
Kiyoshi Okamoto, Tokyo (JP); Junji Matsui, Tsukuba (JP); and Corina Dutcus, Woodcliff Lake, NJ (US)
Assigned to Eisai R&D Management Co., Ltd., Tokyo (JP)
Appl. No. 15/750,712
Filed by Eisai R&D Management Co., Ltd., Tokyo (JP)
PCT Filed Aug. 18, 2016, PCT No. PCT/JP2016/074090 § 371(c)(1), (2) Date Feb. 6, 2018, PCT Pub. No. WO2017/030161, PCT Pub. Date Feb. 23, 2017.
Claims priority of provisional application 62/207,546, filed on Aug. 20, 2015.
Prior Publication US 2019/0000797 A1, Jan. 3, 2019
Int. Cl. A61K 31/357 (2006.01); A61K 31/47 (2006.01); A61K 31/664 (2006.01); A61K 31/675 (2006.01); A61P 35/00 (2006.01); A61K 31/7048 (2006.01)

CPC A61K 31/357 (2013.01) [A61K 31/47 (2013.01); A61K 31/664 (2013.01); A61P 35/00 (2018.01); A61K 31/675 (2013.01); A61K 31/7048 (2013.01); A61K 2300/00 (2013.01)]

7 Claims

1. A method for treating a tumor, comprising administering lenvatinib or a pharmacologically acceptable salt thereof, ifosfamide, and etoposide or a pharmacologically acceptable salt thereof to a patient in need thereof.